Pulsenmore Ltd.

Pulsenmore Ltd. is an Israeli medical device company specializing in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Headquartered in Omer, Israel, with additional offices in Ramat Gan, Israel, and Jericho, New York, USA, the company's mission is to make high-quality ultrasound accessible anytime, anywhere through self-scanning with clinical supervision, thereby revolutionizing maternal health and making healthcare more accessible and patient-driven.

Pulsenmore's key product is the Pulsenmore ES, a home-use prenatal ultrasound platform that enables expectant mothers to perform guided scans at home, with images interpreted by remote physicians. The company's offerings include a handheld ultrasound device that docks with a smartphone, a mobile application for patient consultation, a web application for clinician interaction, and a software API for integration with health records. While primarily focused on prenatal care, telemedicine, and femtech, Pulsenmore is also developing solutions for follicular monitoring (IVF) and exploring applications in pulmonary, cardiology, and urology.

Pulsenmore has established itself as a global pioneer in home ultrasound technology. In November 2025, the company received FDA De Novo marketing authorization for its Pulsenmore ES system, facilitating its phased U.S. launch in early 2026. Following this, Pulsenmore announced its first commercial engagements in the U.S. in early 2026 with the Center for Fetal Medicine & Women's Ultrasound in Los Angeles and TLC Perinatal PA in Maryland. Dr. Elazar Sonnenschein serves as the CEO and founder, with Prof. Israel Meizner as the Chief Medical Officer. GE HealthCare made a strategic investment of up to $50 million in Pulsenmore in 2022, further solidifying its market position.